目的:利用生信分析探讨细胞因子IL-12及IFN-γ对乳腺癌患者免疫微环境的影响,并结合临床病理特征,对其评估新辅助化疗疗效的价值进行研究。方法:在基因表达综合(GEO)数据库中下载GSE163882,比较IL-12相对应基因IL12B及IFN-γ相对应基因I...目的:利用生信分析探讨细胞因子IL-12及IFN-γ对乳腺癌患者免疫微环境的影响,并结合临床病理特征,对其评估新辅助化疗疗效的价值进行研究。方法:在基因表达综合(GEO)数据库中下载GSE163882,比较IL-12相对应基因IL12B及IFN-γ相对应基因IFNG在病理完全缓解(pCR)患者和残留病灶(RD)患者中的表达。收集于我院接受新辅助化疗的50例乳腺癌患者的临床资料,使用卡方检验分析临床病理特征与新辅助化疗疗效的相关性;通过ROC曲线评估血清IL-12、IFN-γ的预测价值,并且确定最佳截断值;采用二元Logistic回归进行多因素分析。通过ssGSEA免疫浸润分析IL12B和IFNG与免疫细胞浸润的相关性;采用GO和KEGG功能富集分析,探讨相关基因潜在生物学功能及信号通路。结果:在GEO数据库GSE163882数据集中IL12B和IFNG在pCR患者中呈现高表达。于我院收治的临床患者中pCR患者化疗前血清IL-12和IFN-γ水平明显高于非pCR组(P γ表达状态显著相关(P γ水平是新辅助化疗疗效的独立影响因素。免疫浸润分析显示,活化CD4 T细胞、活化CD8 T细胞、活化B细胞和自然杀伤细胞在pCR患者中高度浸润。结论:血清IL-12和IFN-γ表达状态与新辅助化疗效果具有相关性,化疗前血清IFN-γ高表达是pCR的独立预测因子。Objective: To investigate the effects of cytokines IL-12 and IFN-γ on the immune microenvironment of breast cancer patients by means of Bioinformatics analysis, and to study their value in evaluating the efficacy of neoadjuvant chemotherapy combined with clinicopathological characteristics. Methods: GSE163882 was downloaded from the Gene Expression Omnibus database, and the expressions of IL-12 corresponding gene IL12B and IFNG corresponding gene IFN-γ were compared in pathologic complete response patients and residual lesion patients. The clinical data of 50 breast cancer patients who received neoadjuvant chemotherapy at The Affiliated Hospital of Qingdao University were collected. Chi-square test was used to analyze the correlation between clinicopathological features and the efficacy of neoadjuvant chemotherapy. The predictive value of serum IL-12 and IFN-γ was evaluated by ROC curve. Multivariate analysis was performed by binary Logistic regression. The correlation between IL12B and IFNG and immune cell infiltration was analyzed by ssGSEA immunoinfiltration. GO and KEGG functional enrichment analysis were used to explore the potential biological functions and signaling pathways of related genes. Results: IL12B and IFNG were highly expressed in pCR patients in the GSE163882 dataset. The serum levels of IL-12 and IFN-γ in pCR patients before chemotherapy were significantly higher than those in non-PCR group (P γ expression after neoadjuvant chemotherapy (P γ level before chemotherapy was an independent factor influencing the efficacy of neoadjuvant chemotherapy. Immunoinfiltration analysis showed that activated CD4 T cells, activated CD8 T cells, activated B cells, and natural killer cells were highly infiltrated in pCR patients. Conclusion: The expression of serum IL-12 and IFN-γ is correlated with the effect of neoadjuvant chemotherapy, and the high expression of serum IFN-γ before chemotherapy is an independent predictor of pCR.展开更多
目的:调查HER-2阴性乳腺癌患者中,不同的HER-2表达水平对新辅助化疗疗效的影响以及与患者临床病理特征的关系。方法:采集青岛大学附属医院乳腺病诊疗中心于2017年1月~2024年1月在我院确诊乳腺癌并接受新辅助化疗的HER-2阴性乳腺癌患者共...目的:调查HER-2阴性乳腺癌患者中,不同的HER-2表达水平对新辅助化疗疗效的影响以及与患者临床病理特征的关系。方法:采集青岛大学附属医院乳腺病诊疗中心于2017年1月~2024年1月在我院确诊乳腺癌并接受新辅助化疗的HER-2阴性乳腺癌患者共164例。将HER-2阴性乳腺癌分为HER-2(0)和HER-2 low两组,分析其临床病理学特征及其与新辅助化疗疗效存在的联系。结果:164例HER-2阴性乳腺癌患者中,总pCR (病理完全缓解)率达到17.1%。HER-2 low乳腺癌患者的pCR率为11.5%,低于HER-2(0)乳腺癌患者的33.3%,其差异有统计学意义(P = 0.001)。同时还发现组织学分级、雌激素受体(ER)和孕激素受体(PR)的状态以及ki-67水平均可能与新辅助化疗疗效相关(P Objective: To investigate the effect of different HER-2 expression levels on the efficacy of neoadjuvant chemotherapy and the relationship with clinicopathological features of patients with HER-2 negative breast cancer. Methods: A total of 164 patients with HER-2 negative breast cancer who were diagnosed with breast cancer and received neoadjuvant chemotherapy in the Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qingdao University from January 2017 to January 2024 were collected. Her-2 negative breast cancer was divided into two groups, HER-2(0) and HER-2 low, and the clinicopathological features of HER-2 negative breast cancer and its relationship with the efficacy of neoadjuvant chemotherapy were analyzed. Results: In 164 patients with HER-2 negative breast cancer, the total pCR rate reached 17.1%. The pCR rate in patients with HER-2 low breast cancer was 11.5%, lower than 33.3% in patients with HER-2(0) breast cancer, and the difference was statistically significant (P = 0.001). It was also found that the status of estrogen receptor (ER) and progesterone receptor (PR) and ki-67 level may be related to the efficacy of neoadjuvant chemotherapy (P < 0.05). Logistic regression analysis showed that histological grade (OR 3.807, 95%CI 1.347~10.758, P = 0.012) and HER-2 expression status (OR 0.380, 95%CI 0.146~0.998, P = 0.047) could independently predict pCR. This conclusion can be used for neoadjuvant chemotherapy for HER-2 negative breast cancer. Conclusion: The difference of HER-2 expression status can significantly affect the efficacy of neoadjuvant chemotherapy for HER-2 negative breast cancer, and HER-2 expression status and histological grade are independent predictors of pCR, which can jointly guide neoadjuvant chemotherapy.展开更多
目的:研究二维斑点追踪成像在浸润性膀胱癌患者新辅助化疗方案(吉西他滨 + 顺铂)后左室收缩功能早期受损的临床应用价值。方法:选取我院2023年6月至2024年12月期间诊断为浸润性膀胱癌患者31例(A组实验组),其中男性23例,女性8例,平均年龄...目的:研究二维斑点追踪成像在浸润性膀胱癌患者新辅助化疗方案(吉西他滨 + 顺铂)后左室收缩功能早期受损的临床应用价值。方法:选取我院2023年6月至2024年12月期间诊断为浸润性膀胱癌患者31例(A组实验组),其中男性23例,女性8例,平均年龄为62.65 ± 10.80岁,采用新辅助化疗(neoadjuvant chemotherapy, NAC) (顺铂 + 吉西他滨)联合根治性膀胱切除术(radical cystectomy, RC)化疗的治疗方案,以28天为一个周期,全部患者在用药前基线水平(T0)、第1周期(T1)、第2周期(T2)、第3周期(T3)结束后48 h内进行常规超声心动图检查及二维斑点追踪成像检查,获取IVSD、LVPWD、LVEDD、LVESD、LVEDV、LVESV、LVEF、LVFS、E、A、E/A、e'、E/e'、LVGLS。另选取非浸润性膀胱癌患者34例作为对照组(B组对照组),并进行一次常规超声心动图检查及二维斑点追踪成像检查,获取与实验组同样数据。比较组间及组内数据的差异性。结果:与T0相比,T1、T2、T3时实验组患者IVSD、LVPWD、LVEDD、LVESD、LVEDV、LVESV均无显著差异(P > 0.05);与T0相比,T1、T2、T3时实验组患者LVEF、LVFS差异无统计学意义(P > 0.05);与T0相比,实验组患者LVGLS于T2、T3时出现降低,差异具有统计学意义(P 0.05),但E、e'随着用药次数的增加呈下降趋势。结论:膀胱癌新辅助化疗后常规超声检查结果在正常范围时,GLS可准确提供左室整体纵向应变的收缩功能参数变化,从而协助临床医生评价化疗后患者心脏早期受损情况。Objective: To investigate the clinical value of two-dimensional spot tracking imaging in the early impaired left ventricular systolic function after neoadjuvant chemotherapy (gemcitabine + cisplatin) in patients with invasive bladder cancer. How: Thirty-one patients (group A experimental group) diagnosed with invasive bladder cancer in our hospital from June 2023 to December 2024, including 23 males and 8 females, with an average age of 62.65 ± 10.80 years old, were selected for neoadjuvant chemotherapy, NAC (cisplatin + gemcitabine) combined with radical cystectomy (RC) chemotherapy, with a 28-day cycle. All patients underwent routine echocardiography and two-dimensional spot tracking imaging within 48 hours after the end of baseline (T0), cycle 1 (T1), cycle 2 (T2), and cycle 3 (T3) before medication. Obtain IVSD, LVPWD, LVEDD, LVESD, LVEDV, LVESV, LVEF, LVFS, E, A, E/A, e', E/e', and LVGLS. In addition, 34 patients with non-invasive bladder cancer were selected as the control group (group B control group), and routine echocardiography and two-dimensional spot tracking imaging were performed to obtain the same data as the experimental group. Compare data differences between and within groups. Results: Compared with T0, there were no significant differences in IVSD, LVPWD, LVEDD, LVESD, LVEDV and LVESV at T1, T2 and T3 (P > 0.05). Compared with T0, there was no significant difference in LVEF and LVFS at T1, T2 and T3 (P > 0.05). Compared with T0, LVGLS in the experimental group decreased at T2 and T3, and the difference was statistically significant (P 0.05), but E' and e' showed a decreasing trend with the increase of the number of administration. Conclusion: When the results of routine ultrasound examination after neoadjuvant chemotherapy for bladder cancer are in the normal range, GLS can accurately provide the change of systolic function parameters of the global longitudinal strain of the left ventricle, so as to assist clinicians in evaluating the early cardiac damage after chemotherapy.展开更多
目的:评价生脉饮口服液对促进卵巢癌新辅助化疗后患者围手术期加速康复的改善作用,探讨生脉饮在加速康复外科中的临床价值。方法:选择2023年5月至2024年1月在中国医学科学院北京协和医学院肿瘤医院就诊的卵巢癌新辅助化疗后的手术患者50...目的:评价生脉饮口服液对促进卵巢癌新辅助化疗后患者围手术期加速康复的改善作用,探讨生脉饮在加速康复外科中的临床价值。方法:选择2023年5月至2024年1月在中国医学科学院北京协和医学院肿瘤医院就诊的卵巢癌新辅助化疗后的手术患者50例,使用随机数字表法将其分为生脉饮组和常规组,每组各25例。常规组接受术后常规治疗,生脉饮组在术后常规治疗的基础上,应用生脉饮口服液。采用中国癌症患者生活质量调查问卷(quality of life questionnaire for Chinese cancer patients,QLQ)评估两组患者术后第1天、第7天和第14天的生活质量。观察两组患者术后恢复指标以及安全性指标,包括术后首次排气时间、术后首次排便时间、引流管留置时间、术后住院时间,以及血常规、肝功能、肾功能、心肌酶及心电图。结果:生脉饮组患者术后第1天、第7天、第14天QLQ评分均明显高于常规组患者(均P<0.05);两组患者术后首次排气时间、术后首次排便时间、引流管留置时间、术后住院时间和安全性指标比较,差异均无统计学意义(均P>0.05)。结论:生脉饮口服液可提高新辅助化疗后卵巢癌患者术后生活质量。展开更多
文摘目的:利用生信分析探讨细胞因子IL-12及IFN-γ对乳腺癌患者免疫微环境的影响,并结合临床病理特征,对其评估新辅助化疗疗效的价值进行研究。方法:在基因表达综合(GEO)数据库中下载GSE163882,比较IL-12相对应基因IL12B及IFN-γ相对应基因IFNG在病理完全缓解(pCR)患者和残留病灶(RD)患者中的表达。收集于我院接受新辅助化疗的50例乳腺癌患者的临床资料,使用卡方检验分析临床病理特征与新辅助化疗疗效的相关性;通过ROC曲线评估血清IL-12、IFN-γ的预测价值,并且确定最佳截断值;采用二元Logistic回归进行多因素分析。通过ssGSEA免疫浸润分析IL12B和IFNG与免疫细胞浸润的相关性;采用GO和KEGG功能富集分析,探讨相关基因潜在生物学功能及信号通路。结果:在GEO数据库GSE163882数据集中IL12B和IFNG在pCR患者中呈现高表达。于我院收治的临床患者中pCR患者化疗前血清IL-12和IFN-γ水平明显高于非pCR组(P γ表达状态显著相关(P γ水平是新辅助化疗疗效的独立影响因素。免疫浸润分析显示,活化CD4 T细胞、活化CD8 T细胞、活化B细胞和自然杀伤细胞在pCR患者中高度浸润。结论:血清IL-12和IFN-γ表达状态与新辅助化疗效果具有相关性,化疗前血清IFN-γ高表达是pCR的独立预测因子。Objective: To investigate the effects of cytokines IL-12 and IFN-γ on the immune microenvironment of breast cancer patients by means of Bioinformatics analysis, and to study their value in evaluating the efficacy of neoadjuvant chemotherapy combined with clinicopathological characteristics. Methods: GSE163882 was downloaded from the Gene Expression Omnibus database, and the expressions of IL-12 corresponding gene IL12B and IFNG corresponding gene IFN-γ were compared in pathologic complete response patients and residual lesion patients. The clinical data of 50 breast cancer patients who received neoadjuvant chemotherapy at The Affiliated Hospital of Qingdao University were collected. Chi-square test was used to analyze the correlation between clinicopathological features and the efficacy of neoadjuvant chemotherapy. The predictive value of serum IL-12 and IFN-γ was evaluated by ROC curve. Multivariate analysis was performed by binary Logistic regression. The correlation between IL12B and IFNG and immune cell infiltration was analyzed by ssGSEA immunoinfiltration. GO and KEGG functional enrichment analysis were used to explore the potential biological functions and signaling pathways of related genes. Results: IL12B and IFNG were highly expressed in pCR patients in the GSE163882 dataset. The serum levels of IL-12 and IFN-γ in pCR patients before chemotherapy were significantly higher than those in non-PCR group (P γ expression after neoadjuvant chemotherapy (P γ level before chemotherapy was an independent factor influencing the efficacy of neoadjuvant chemotherapy. Immunoinfiltration analysis showed that activated CD4 T cells, activated CD8 T cells, activated B cells, and natural killer cells were highly infiltrated in pCR patients. Conclusion: The expression of serum IL-12 and IFN-γ is correlated with the effect of neoadjuvant chemotherapy, and the high expression of serum IFN-γ before chemotherapy is an independent predictor of pCR.
文摘目的:调查HER-2阴性乳腺癌患者中,不同的HER-2表达水平对新辅助化疗疗效的影响以及与患者临床病理特征的关系。方法:采集青岛大学附属医院乳腺病诊疗中心于2017年1月~2024年1月在我院确诊乳腺癌并接受新辅助化疗的HER-2阴性乳腺癌患者共164例。将HER-2阴性乳腺癌分为HER-2(0)和HER-2 low两组,分析其临床病理学特征及其与新辅助化疗疗效存在的联系。结果:164例HER-2阴性乳腺癌患者中,总pCR (病理完全缓解)率达到17.1%。HER-2 low乳腺癌患者的pCR率为11.5%,低于HER-2(0)乳腺癌患者的33.3%,其差异有统计学意义(P = 0.001)。同时还发现组织学分级、雌激素受体(ER)和孕激素受体(PR)的状态以及ki-67水平均可能与新辅助化疗疗效相关(P Objective: To investigate the effect of different HER-2 expression levels on the efficacy of neoadjuvant chemotherapy and the relationship with clinicopathological features of patients with HER-2 negative breast cancer. Methods: A total of 164 patients with HER-2 negative breast cancer who were diagnosed with breast cancer and received neoadjuvant chemotherapy in the Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qingdao University from January 2017 to January 2024 were collected. Her-2 negative breast cancer was divided into two groups, HER-2(0) and HER-2 low, and the clinicopathological features of HER-2 negative breast cancer and its relationship with the efficacy of neoadjuvant chemotherapy were analyzed. Results: In 164 patients with HER-2 negative breast cancer, the total pCR rate reached 17.1%. The pCR rate in patients with HER-2 low breast cancer was 11.5%, lower than 33.3% in patients with HER-2(0) breast cancer, and the difference was statistically significant (P = 0.001). It was also found that the status of estrogen receptor (ER) and progesterone receptor (PR) and ki-67 level may be related to the efficacy of neoadjuvant chemotherapy (P < 0.05). Logistic regression analysis showed that histological grade (OR 3.807, 95%CI 1.347~10.758, P = 0.012) and HER-2 expression status (OR 0.380, 95%CI 0.146~0.998, P = 0.047) could independently predict pCR. This conclusion can be used for neoadjuvant chemotherapy for HER-2 negative breast cancer. Conclusion: The difference of HER-2 expression status can significantly affect the efficacy of neoadjuvant chemotherapy for HER-2 negative breast cancer, and HER-2 expression status and histological grade are independent predictors of pCR, which can jointly guide neoadjuvant chemotherapy.
文摘目的:研究二维斑点追踪成像在浸润性膀胱癌患者新辅助化疗方案(吉西他滨 + 顺铂)后左室收缩功能早期受损的临床应用价值。方法:选取我院2023年6月至2024年12月期间诊断为浸润性膀胱癌患者31例(A组实验组),其中男性23例,女性8例,平均年龄为62.65 ± 10.80岁,采用新辅助化疗(neoadjuvant chemotherapy, NAC) (顺铂 + 吉西他滨)联合根治性膀胱切除术(radical cystectomy, RC)化疗的治疗方案,以28天为一个周期,全部患者在用药前基线水平(T0)、第1周期(T1)、第2周期(T2)、第3周期(T3)结束后48 h内进行常规超声心动图检查及二维斑点追踪成像检查,获取IVSD、LVPWD、LVEDD、LVESD、LVEDV、LVESV、LVEF、LVFS、E、A、E/A、e'、E/e'、LVGLS。另选取非浸润性膀胱癌患者34例作为对照组(B组对照组),并进行一次常规超声心动图检查及二维斑点追踪成像检查,获取与实验组同样数据。比较组间及组内数据的差异性。结果:与T0相比,T1、T2、T3时实验组患者IVSD、LVPWD、LVEDD、LVESD、LVEDV、LVESV均无显著差异(P > 0.05);与T0相比,T1、T2、T3时实验组患者LVEF、LVFS差异无统计学意义(P > 0.05);与T0相比,实验组患者LVGLS于T2、T3时出现降低,差异具有统计学意义(P 0.05),但E、e'随着用药次数的增加呈下降趋势。结论:膀胱癌新辅助化疗后常规超声检查结果在正常范围时,GLS可准确提供左室整体纵向应变的收缩功能参数变化,从而协助临床医生评价化疗后患者心脏早期受损情况。Objective: To investigate the clinical value of two-dimensional spot tracking imaging in the early impaired left ventricular systolic function after neoadjuvant chemotherapy (gemcitabine + cisplatin) in patients with invasive bladder cancer. How: Thirty-one patients (group A experimental group) diagnosed with invasive bladder cancer in our hospital from June 2023 to December 2024, including 23 males and 8 females, with an average age of 62.65 ± 10.80 years old, were selected for neoadjuvant chemotherapy, NAC (cisplatin + gemcitabine) combined with radical cystectomy (RC) chemotherapy, with a 28-day cycle. All patients underwent routine echocardiography and two-dimensional spot tracking imaging within 48 hours after the end of baseline (T0), cycle 1 (T1), cycle 2 (T2), and cycle 3 (T3) before medication. Obtain IVSD, LVPWD, LVEDD, LVESD, LVEDV, LVESV, LVEF, LVFS, E, A, E/A, e', E/e', and LVGLS. In addition, 34 patients with non-invasive bladder cancer were selected as the control group (group B control group), and routine echocardiography and two-dimensional spot tracking imaging were performed to obtain the same data as the experimental group. Compare data differences between and within groups. Results: Compared with T0, there were no significant differences in IVSD, LVPWD, LVEDD, LVESD, LVEDV and LVESV at T1, T2 and T3 (P > 0.05). Compared with T0, there was no significant difference in LVEF and LVFS at T1, T2 and T3 (P > 0.05). Compared with T0, LVGLS in the experimental group decreased at T2 and T3, and the difference was statistically significant (P 0.05), but E' and e' showed a decreasing trend with the increase of the number of administration. Conclusion: When the results of routine ultrasound examination after neoadjuvant chemotherapy for bladder cancer are in the normal range, GLS can accurately provide the change of systolic function parameters of the global longitudinal strain of the left ventricle, so as to assist clinicians in evaluating the early cardiac damage after chemotherapy.
文摘目的:评价生脉饮口服液对促进卵巢癌新辅助化疗后患者围手术期加速康复的改善作用,探讨生脉饮在加速康复外科中的临床价值。方法:选择2023年5月至2024年1月在中国医学科学院北京协和医学院肿瘤医院就诊的卵巢癌新辅助化疗后的手术患者50例,使用随机数字表法将其分为生脉饮组和常规组,每组各25例。常规组接受术后常规治疗,生脉饮组在术后常规治疗的基础上,应用生脉饮口服液。采用中国癌症患者生活质量调查问卷(quality of life questionnaire for Chinese cancer patients,QLQ)评估两组患者术后第1天、第7天和第14天的生活质量。观察两组患者术后恢复指标以及安全性指标,包括术后首次排气时间、术后首次排便时间、引流管留置时间、术后住院时间,以及血常规、肝功能、肾功能、心肌酶及心电图。结果:生脉饮组患者术后第1天、第7天、第14天QLQ评分均明显高于常规组患者(均P<0.05);两组患者术后首次排气时间、术后首次排便时间、引流管留置时间、术后住院时间和安全性指标比较,差异均无统计学意义(均P>0.05)。结论:生脉饮口服液可提高新辅助化疗后卵巢癌患者术后生活质量。
